During 2QFY2024, the Company identified an alternative PCSK9 inhibitor candidate. The compound was manufactured, and preliminary assessments were undertaken. It was however determined that the commercial risk/reward profile of this alternative candidate did not warrant further investigation.
Nyrada maintains the view that a small molecule oral PCSK9 inhibitor is the optimal treatment for hypercholesterolemia, for which there is a significant and viable market. Low-cost background work is continuing to determine Nyrada’s available pathways for developing an effective and commercially viable PCSK9 inhibitor.
NYR Price at posting:
2.3¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)